Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial

Diabetes Care
Lawrence A LeiterSAVOR-TIMI 53 Steering Committee and Investigators

Abstract

To examine the safety and cardiovascular (CV) effects of saxagliptin in the predefined elderly (≥65 years) and very elderly (≥75 years) subpopulations of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial. Individuals ≥40 years (n = 16,492; elderly, n = 8,561; very elderly, n = 2,330) with HbA1c ≥6.5% (47.5 mmol/mol) and ≤12.0% (107.7 mmol/mol) were randomized (1:1) to saxagliptin (5 or 2.5 mg daily) or placebo in a double-blind trial for a median follow-up of 2.1 years. The hazard ratio (HR) for the comparison of saxagliptin versus placebo for the primary end point (composite of CV mortality, myocardial infarction, or ischemic stroke) was 0.92 for elderly patients vs. 1.15 for patients <65 years (P = 0.06) and 0.95 for very elderly patients. The HRs for the secondary composite end points in the entire cohort, elderly cohort, and very elderly cohort were similar. Although saxagliptin increased the risk of hospitalization for heart failure in the overall saxagliptin population, there was no age-based treatment interaction (P = 0.76 for elderly patients vs. those <65 years; P = 0.34 for very elderly patients vs. those <75 years...Continue Reading

References

Oct 26, 2002·BMJ : British Medical Journal·Edward W GreggVenkat Narayan
Jun 2, 2009·The American Journal of Medicine·Matthew P Gilbert, Richard E Pratley
Oct 2, 2009·Journal of the American Geriatrics Society·Richard E PratleyQais Mekki
Oct 28, 2009·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Helena W RodbardStanley S Schwartz
Feb 18, 2011·Current Medical Research and Opinion·Jean DoucetJulio Rosenstock
Mar 2, 2011·Archives of Internal Medicine·Medha N MunshiKatie Weinger
Dec 14, 2011·Current Medical Research and Opinion·Matteo MonamiEdoardo Mannucci
Oct 27, 2012·Diabetes Care·M Sue KirkmanCarrie S Swift
Feb 19, 2013·Diabetes Care·Sarah Stark CasagrandeCatherine C Cowie
Mar 2, 2013·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Julio RosenstockHans-Jürgen Woerle
Mar 26, 2013·Diabetes Research and Clinical Practice·Leonor Guariguata
Apr 18, 2013·Journal of the American Geriatrics Society·Alfonso J Cruz-JentoftElisabet Sánchez-García
May 24, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Samuel S EngelBarry J Goldstein
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 28, 2013·Canadian Journal of Diabetes·Lawrence A LeiterAnatoly Langer
Dec 3, 2013·Diabetes Research and Clinical Practice·UNKNOWN International Diabetes Federation
Jan 1, 2014·Diabetes/metabolism Research and Reviews·Boaz HirshbergNayyar Iqbal
Jun 28, 2014·Drug Design, Development and Therapy·Antoni Sicras-Mainar, Ruth Navarro-Artieda

❮ Previous
Next ❯

Citations

Jan 12, 2016·Canadian Journal of Diabetes·Mousumi SircarMedha Munshi
Oct 8, 2015·Diabetes, Obesity & Metabolism·L A LeiterUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Nov 28, 2015·Journal of the American Medical Directors Association·Chia-Jen ShihYung-Tai Chen
Sep 26, 2015·Drugs·Sohita Dhillon
Mar 1, 2016·Expert Opinion on Drug Safety·Simona CerneaItamar Raz
Oct 8, 2016·Cardiovascular Diabetology·Oliver SchnellUNKNOWN D&CVD EASD Study Group
Nov 5, 2016·Expert Opinion on Emerging Drugs·Avivit CahnItamar Raz
Feb 23, 2018·Expert Opinion on Drug Safety·André Jacques Scheen
Jul 12, 2017·World Journal of Diabetes·Konstantinos Avgerinos, Konstantinos Tziomalos
Oct 7, 2017·Expert Review of Clinical Pharmacology·André J Scheen
Jul 6, 2018·Expert Opinion on Drug Safety·María Molina-VegaFrancisco J Tinahones
Feb 7, 2019·Postgraduate Medicine·Jeffrey Freeman
Apr 26, 2019·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Nordin Mj Hanssen, Karin Am Jandeleit-Dahm
Oct 13, 2017·Cardiovascular Diabetology·Oliver SchnellUNKNOWN D&CVD EASD Study Group
Sep 30, 2015·Cardiovascular Diabetology·Enrique Z Fisman, Alexander Tenenbaum
Sep 7, 2018·Current Diabetes Reports·Willy Marcos ValenciaStuti Dang
Sep 16, 2020·Nature Reviews. Endocrinology·Carolyn F Deacon
Jan 25, 2018·Diabetes, Obesity & Metabolism·Carolyn F Deacon
Dec 11, 2020·Diabetes Care·UNKNOWN American Diabetes Association
Feb 18, 2020·Pharmacology & Therapeutics·Shiying ShaoYong Chen
Apr 8, 2021·Expert Opinion on Pharmacotherapy·André J Scheen
Jun 27, 2021·Nature Reviews. Endocrinology·Srikanth BellaryClifford J Bailey
Nov 11, 2020·Current Pharmaceutical Design·Gerasimos SiasosDimitrios Tousoulis
Nov 28, 2020·Current Pharmaceutical Design·Andrea DemarchiEmmanuel Androulakis
Dec 30, 2021·Diabetes Care·UNKNOWN American Diabetes Association Professional Practice CommitteeMikhail Kosiborod

❮ Previous
Next ❯

Related Concepts

Related Feeds

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.